Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study.
Aged
CD8-Positive T-Lymphocytes
/ immunology
Female
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immunotherapy
/ methods
Male
Melanoma
/ drug therapy
Middle Aged
Myeloid-Derived Suppressor Cells
/ drug effects
Paclitaxel
/ administration & dosage
Pilot Projects
Skin Neoplasms
/ immunology
Tumor Microenvironment
/ immunology
Immune checkpoint blockade
Immunotherapy
Melanoma
Myeloid suppressor cells
Paclitaxel
Journal
Cellular immunology
ISSN: 1090-2163
Titre abrégé: Cell Immunol
Pays: Netherlands
ID NLM: 1246405
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
23
11
2020
revised:
15
12
2020
accepted:
18
12
2020
pubmed:
1
1
2021
medline:
29
6
2021
entrez:
31
12
2020
Statut:
ppublish
Résumé
The low dose application of chemotherapeutic agents such as paclitaxel was previously shown to initiate anti-tumor activity by neutralizing myeloid-derived suppressor cells (MDSCs) in melanoma mouse models. Here, we investigated immunomodulating effects of low-dose paclitaxel in 9 metastatic melanoma patients resistant to prior treatments. Three patients showed response to therapy (two partial responses and one stable disease). In responding patients, paclitaxel decreased the frequency and immunosuppressive pattern of MDSCs in the peripheral blood and skin metastases. Furthermore, paclitaxel modulated levels of inflammatory mediators in the serum. In addition, responders displayed enhanced frequencies of tumor-infiltrating CD8
Identifiants
pubmed: 33383383
pii: S0008-8749(20)30434-2
doi: 10.1016/j.cellimm.2020.104274
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104274Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.